| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.23 | -0.01 (-0.45%) | 1.33 - 3.16 | 49.2 thousand (Below Avg) |
Market data as of 4:06PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 2.32 |
|---|---|
| Previous Close | 2.24 |
| Day's Range | 2.23 - 2.34 |
| Market Cap | 87.8M |
| Avg Volume (10 Day) | 57.4K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.02 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Enzo and NIH File Patent Application for Therapies, Diagnosis, and Prognosis for Autoimmune Diseases
Business Wire - Tuesday 05/07/2013 8:30 AM ET
| ENZ | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -3.07% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 0.88 |
| Company | Last | Change |
|---|---|---|
| LipoScience Inc | 6.19 | +0.65% |
| RadNet Inc | 2.38 | -2.46% |
| Psychemedics Corp | 11.40 | -0.44% |
| BG Medicine Inc | 1.72 | -3.91% |
| Response Genetics Inc | 1.42 | 0.00% |
Data is delayed by at least 15 min.